Chemical Works of Gedeon Richter Plc
ISIN: HU0000123096 | Ticker: RICHT | LEI: 549300J6ZJW5IH4WEE46
Country: Hungary
Headquartered in Hungary, Gedeon Richter Plc. is an innovation-driven specialty pharmaceutical company.
The activities of the Hungarian-directed multinational company are vertically integrated and involve pharmaceutical manufacturing, research and development, sales and marketing. Richter’s goal is to help the public fight off illnesses with innovative products and, by doing so, help improve the quality of human life.
The goal of Gedeon Richter Plc.'s business strategy for the period 2018-2028 is to become a prominent player in the league of European-based midpharma companies.
1901
Served areaWorldwide
Headcount12,842
HeadquartersGyömrői út 19-21, 1103 Budapest – Hungary
| Line item in (huf) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 948,589,000,000.00 | 1,145,282,000,000.00 | 1,340,289,000,000.00 |
| Noncurrent Assets | N/A | 499,071,000,000.00 | 732,660,000,000.00 | 764,519,000,000.00 |
| Property Plant And Equipment | N/A | 254,121,000,000.00 | 278,394,000,000.00 | 315,949,000,000.00 |
| Investment Property | N/A | 110,000,000.00 | 110,000,000.00 | 0.00 |
| Goodwill | N/A | 31,398,000,000.00 | 35,005,000,000.00 | 35,101,000,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 141,303,000,000.00 | 220,915,000,000.00 | 196,714,000,000.00 |
| Investment Accounted For Using Equity Method | N/A | 12,269,000,000.00 | 10,800,000,000.00 | 9,281,000,000.00 |
| Other Noncurrent Receivables | N/A | 2,547,000,000.00 | 2,784,000,000.00 | 3,432,000,000.00 |
| Deferred Tax Assets | N/A | 7,139,000,000.00 | 12,285,000,000.00 | 15,878,000,000.00 |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | N/A | 10,797,000,000.00 | 93,758,000,000.00 | 67,724,000,000.00 |
| Noncurrent Financial Assets At Fair Value Through Other Comprehensive Income | N/A | 38,216,000,000.00 | 73,274,000,000.00 | 68,193,000,000.00 |
| Noncurrent Financial Assets At Amortised Cost | N/A | 1,171,000,000.00 | 5,335,000,000.00 | 20,801,000,000.00 |
| Noncurrent Derivative Financial Assets | N/A | N/A | 9,107,000,000.00 | 31,446,000,000.00 |
| Current Assets | N/A | 449,518,000,000.00 | 412,622,000,000.00 | 575,770,000,000.00 |
| Inventories | N/A | 110,059,000,000.00 | 131,349,000,000.00 | 153,335,000,000.00 |
| Current Trade Receivables | N/A | 152,652,000,000.00 | 184,760,000,000.00 | 175,182,000,000.00 |
| Current Tax Assets Current | N/A | 1,196,000,000.00 | 1,110,000,000.00 | 4,844,000,000.00 |
| Current Financial Assets At Fair Value Through Other Comprehensive Income | N/A | N/A | 0.00 | 1,536,000,000.00 |
| Current Financial Assets At Amortised Cost | N/A | 371,000,000.00 | 912,000,000.00 | 44,716,000,000.00 |
| Other Current Nonfinancial Assets | N/A | 27,162,000,000.00 | 30,474,000,000.00 | 41,120,000,000.00 |
| Cash and cash equivalents | 128,573,000,000.00 | 142,068,000,000.00 | 59,856,000,000.00 | 79,719,000,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 5,788,000,000.00 | 0.00 | 67,014,000,000.00 |
| Current Derivative Financial Assets | N/A | N/A | 296,000,000.00 | 2,154,000,000.00 |
| Equity And Liabilities | N/A | 948,589,000,000.00 | 1,145,282,000,000.00 | 1,340,289,000,000.00 |
| Equity | 724,873,000,000.00 | 813,939,000,000.00 | 923,022,000,000.00 | 1,060,352,000,000.00 |
| Issued Capital | N/A | 18,638,000,000.00 | 18,638,000,000.00 | 18,638,000,000.00 |
| Retained Earnings | N/A | 751,408,000,000.00 | 849,735,000,000.00 | 966,375,000,000.00 |
| Share Premium | N/A | 15,214,000,000.00 | 15,214,000,000.00 | 15,214,000,000.00 |
| Treasury Shares | N/A | 3,791,000,000.00 | 2,862,000,000.00 | 2,123,000,000.00 |
| Capital Reserve | N/A | 3,475,000,000.00 | 3,475,000,000.00 | 3,475,000,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 806,957,000,000.00 | 914,886,000,000.00 | 1,049,906,000,000.00 |
| Noncontrolling Interests | N/A | 6,982,000,000.00 | 8,136,000,000.00 | 10,446,000,000.00 |
| Noncurrent Liabilities | N/A | 26,712,000,000.00 | 99,047,000,000.00 | 100,430,000,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 6,653,000,000.00 | 5,878,000,000.00 | 5,079,000,000.00 |
| Other Noncurrent Payables | N/A | 6,747,000,000.00 | 12,830,000,000.00 | 13,634,000,000.00 |
| Deferred Tax Liabilities | N/A | 1,753,000,000.00 | 3,798,000,000.00 | 3,928,000,000.00 |
| Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss | N/A | 805,000,000.00 | 63,819,000,000.00 | 41,516,000,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | N/A | 8,518,000,000.00 | 25,484,000,000.00 |
| Current Liabilities | N/A | 107,938,000,000.00 | 123,213,000,000.00 | 179,507,000,000.00 |
| Current Provisions | N/A | 4,866,000,000.00 | 3,121,000,000.00 | 2,153,000,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 65,838,000,000.00 | 79,638,000,000.00 | 46,092,000,000.00 |
| Current Contract Liabilities | N/A | 772,000,000.00 | 1,593,000,000.00 | 1,931,000,000.00 |
| Current Tax Liabilities Current | N/A | 1,993,000,000.00 | 2,722,000,000.00 | 3,848,000,000.00 |
| Current Financial Liabilities At Fair Value Through Profit Or Loss | N/A | 4,014,000,000.00 | 3,277,000,000.00 | 2,855,000,000.00 |
| Other Current Nonfinancial Liabilities | N/A | 24,918,000,000.00 | 28,267,000,000.00 | 64,361,000,000.00 |
| Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 1,735,000,000.00 | 0.00 | 49,044,000,000.00 |
| Current Derivative Financial Liabilities | N/A | N/A | 85,000,000.00 | 4,786,000,000.00 |
| Line item in (huf) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 566,776,000,000.00 | 630,595,000,000.00 | 802,755,000,000.00 |
| Other Income | N/A | 12,998,000,000.00 | 23,688,000,000.00 |
| Other Expense By Nature | N/A | 22,491,000,000.00 | 74,702,000,000.00 |
| Profit Loss From Operating Activities | 115,089,000,000.00 | 135,832,000,000.00 | 153,555,000,000.00 |
| Finance Income | 28,780,000,000.00 | 30,106,000,000.00 | 88,803,000,000.00 |
| Finance Costs | 29,605,000,000.00 | 22,473,000,000.00 | 82,845,000,000.00 |
| Impairment Loss Impairment Gain And Reversal Of Impairment Loss Determined In Accordance With I F R S9 | -1,329,000,000.00 | -318,000,000.00 | -1,564,000,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 900,000,000.00 | 3,110,000,000.00 | 6,150,000,000.00 |
| Profit Loss Before Tax | 115,164,000,000.00 | 146,575,000,000.00 | 165,663,000,000.00 |
| Income Tax Expense Continuing Operations | 9,112,000,000.00 | 5,395,000,000.00 | 8,408,000,000.00 |
| Profit (loss) | 106,052,000,000.00 | 141,180,000,000.00 | 157,255,000,000.00 |
| Profit Loss Attributable To Owners Of Parent | 104,683,000,000.00 | 139,626,000,000.00 | 155,581,000,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 1,369,000,000.00 | 1,554,000,000.00 | 1,674,000,000.00 |
| Line item in (huf) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 106,052,000,000.00 | 141,180,000,000.00 | 157,255,000,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -13,900,000,000.00 | -20,983,000,000.00 | -38,994,000,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 39,846,000,000.00 | 44,922,000,000.00 | 48,569,000,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | 8,256,000,000.00 | 2,591,000,000.00 | N/A |
| Adjustments For Sharebased Payments | N/A | 1,642,000,000.00 | 1,590,000,000.00 | 1,552,000,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 22,000,000.00 | 27,000,000.00 | 7,256,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 7,515,000,000.00 | 8,136,000,000.00 | 14,290,000,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 133,520,000,000.00 | 139,904,000,000.00 | 184,927,000,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | 2,118,000,000.00 | 0.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | N/A | 0.00 | 1,263,000,000.00 |
| Other Cash Receipts From Sales Of Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 10,807,000,000.00 | 30,998,000,000.00 | 13,523,000,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 47,454,000,000.00 | 143,206,000,000.00 | 57,723,000,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 432,000,000.00 | 1,857,000,000.00 | 2,807,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 36,903,000,000.00 | 46,127,000,000.00 | 59,231,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 29,735,000,000.00 | 97,170,000,000.00 | 12,348,000,000.00 |
| Proceeds From Government Grants Classified As Investing Activities | N/A | 2,197,000,000.00 | 693,000,000.00 | 0.00 |
| Dividends Received Classified As Investing Activities | N/A | 2,000,000.00 | 9,000,000.00 | 43,000,000.00 |
| Interest Received Classified As Investing Activities | N/A | 915,000,000.00 | 2,950,000,000.00 | 13,418,000,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -98,891,000,000.00 | -249,172,000,000.00 | -118,827,000,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 1,650,000,000.00 | 819,000,000.00 | 1,326,000,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 315,119,000,000.00 | 178,487,000,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 244,846,000,000.00 | 178,487,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,143,000,000.00 | 2,055,000,000.00 | 3,437,000,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 13,500,000,000.00 | 42,140,000,000.00 | 42,146,000,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -18,293,000,000.00 | 25,259,000,000.00 | -46,909,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 16,336,000,000.00 | -84,009,000,000.00 | 19,191,000,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -2,647,000,000.00 | 1,603,000,000.00 | 1,632,000,000.00 |
| Cash and cash equivalents | 128,573,000,000.00 | 142,068,000,000.00 | 59,856,000,000.00 | 79,719,000,000.00 |
Please note that some sums might not add up.
HU0000123096
LEI549300J6ZJW5IH4WEE46
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryBUX
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.